Evidence map›Paper›PMID 23928733›Full record

ArticleCancer gene therapy2013

Augmented adenovirus transduction of murine T lymphocytes utilizing a bi-specific protein targeting murine interleukin 2 receptor.

M S Beatty, L Timares, D T Curiel

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Cancer gene therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

M S BeattyDepartment of Radiation Oncology, Washington University School of Medicine in St Louis, St Louis, MO 63108, USA.
L Timares
D T Curiel

Funding

UAB Skin Diseases Research CenterP30AR050948 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ELMETS, CRAIG A · 2004 to 2013
$5.5M
Bid Regulation of Cutaneous Photodamage ResponsesR21AR055252 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI TIMARES, LAURA · 2009 to 2010
$360k
NIAMS NIH HHS P30AR050948NIAMS NIH HHS R21AR055252
6 · The paper itself

Abstract

Adenoviruses are currently used in a variety of bench and bedside applications. However, their employment in gene delivery to lymphocyte lineages is hampered by the lack of coxsackie virus and adenovirus receptor (CAR) on the cell surface. Exploitation of an alternative receptor on the surface of T lymphocytes can allow for utilization of adenovirus in a variety of T lymphocyte-based diseases and therapies. Here, we describe how resistance to infection can be overcome by the utilization of a bi-specific fusion protein, soluble CAR murine interleukin 2 (sCAR-mIL-2), that retargets adenovirus to the murine IL-2 receptor (IL-2R). Infection of a murine T-cell line, CTLL-2, with a sCAR-mIL-2/Adenovirus conjugate provided a ninefold increase in both green fluorescence protein-positive cells and luciferase expression. In addition, this increase in infection was also seen in isolated primary murine T lymphocytes. In this context, the sCAR-mIL-2 adapter provided a fourfold gene transduction increase in activated primary murine T lymphocytes. Our results show that recombinant sCAR-mIL-2 fusion protein promotes IL-2R-targeted gene transfer to murine T lymphocytes and that alternative targeting can abrogate their native resistance to infection.

Indexed as

Gene Transfer TechniquesAdenoviridaeAnimalsCell Growth ProcessesCoxsackie and Adenovirus Receptor-Like Membrane ProteinHEK293 CellsHumansMiceMice, Inbred C57BLReceptors, Interleukin-2Recombinant Fusion ProteinsT-LymphocytesTransduction, GeneticCoxsackie and Adenovirus Receptor-Like Membrane ProteinReceptors, Interleukin-2Recombinant Fusion Proteins

Identifiers

PMID23928733

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.